TCGA-FD-A3B7-01A-31R-A20F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.007884363
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.650
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.610
- ALLOGRAFT_REJECTION+0.570
- IL6_JAK_STAT3_SIGNALING+0.540
- INFLAMMATORY_RESPONSE+0.510
- INTERFERON_ALPHA_RESPONSE+0.460
- INTERFERON_GAMMA_RESPONSE+0.460
- APICAL_JUNCTION+0.430
- COMPLEMENT+0.430
- G2M_CHECKPOINT+0.420
Top 10 suppressed
- PEROXISOME-0.370
- FATTY_ACID_METABOLISM-0.340
- OXIDATIVE_PHOSPHORYLATION-0.340
- ADIPOGENESIS-0.280
- BILE_ACID_METABOLISM-0.210
- PANCREAS_BETA_CELLS-0.150
- CHOLESTEROL_HOMEOSTASIS-0.140
- KRAS_SIGNALING_DN-0.140
- XENOBIOTIC_METABOLISM-0.120
- ESTROGEN_RESPONSE_LATE-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.927 |
| 2 | BS_NR3P3GN2 | high-grade glioma | — | 0.919 |
| 3 | TCGA-50-6595-01A-12R-1858-07 | — | cohortA1 | 0.913 |
| 4 | TCGA-44-7661-01A-11R-2066-07 | — | cohortA1 | 0.907 |
| 5 | TCGA-56-8201-01A-11R-2247-07 | — | cohortA1 | 0.906 |
| 6 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.901 |
| 7 | TCGA-55-6978-01A-11R-1949-07 | — | cohortA1 | 0.899 |
| 8 | R409 | — | — | 0.897 |
| 9 | TCGA-FD-A6TK-01A-42R-A33J-07 | — | — | 0.896 |
| 10 | SRR10900575 | — | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.650 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.610 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.540 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.430 | Inavolisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |